Skip to main content
Top
Published in: BMC Infectious Diseases 1/2019

Open Access 01-12-2019 | Human Immunodeficiency Virus | Research article

DOES IT WORK? -a randomized controlled trial to test the efficacy of HCV and HIV-related education on drug users in MMT, China

Authors: Jing Ying Zhang, Zhi Bin Li, Lei Zhang, Jun Wang, Le Ping Huang, Gui Lai Zhan, Zhu Li, Jiang Du, Min Zhao

Published in: BMC Infectious Diseases | Issue 1/2019

Login to get access

Abstract

Background

HCV (Hepatitis C virus) is a prevalent chronic disease with potentially deadly consequences, especially for drug users. However, there are no special HCV or HIV (human immunodeficiency virus)-related intervention programs that are tailored for drug users in China; to fill this gap, the purpose of this study was to explore HCV and HIV-related knowledge among drug users in MMT (methadone maintenance treatment) sites of China and to investigate the effectiveness of HCV and HIV-related education for improving the knowledge of IDUs (injection drug users) and their awareness of infection.

Methods

The study was a randomized cluster controlled trial that compared a usual care group to a usual care plus HCV/HIV-REP (HCV/HIV-Reduction Education Program) group with a 24-week follow-up. The self-designed questionnaires, the HCV- and HIV-related knowledge questionnaire and the HIV/HCV infection awareness questionnaire, were used to collect the data. Four MMT clinics were selected for this project; two MMT clinics were randomly assigned to the research group, with subjects receiving their usual care plus HCV/HIV-REP, and the remaining two MMT clinics were the control group, with subjects receiving their usual care over 12 weeks. Sixty patients were recruited from each MMT clinic. A total of 240 patients were recruited. Follow-up studies were conducted at the end of the 12th week and the 24th week after the intervention.

Results

At baseline, the mean score (out of 20 possible correct answers) for HCV knowledge among the patients in the group receiving the intervention was 6.51 (SD = 3.5), and it was 20.57 (SD = 6.54) for HIV knowledge (out of 45 correct answers) and 8.35 (SD = 2.8) for HIV/HCV infection awareness (out of 20 correct answers). At the 12-week and 24-week follow-up assessments, the research group showed a greater increase in HCV−/HIV-related knowledge (group × time effect, F = 37.444/11.281, P < 0.05) but no difference in their HIV/HCV infection awareness (group × time effect, F = 2.056, P > 0.05).

Conclusion

An MMT-based HCV/HIV intervention program could be used to improve patient knowledge of HCV and HIV prevention, but more effort should be devoted to HIV/HCV infection awareness.

Trial registration

Protocols for this study were approved by institution review board (IRB) of Shanghai Mental Health Center (IRB:2009036), and registered in U.S national institutes of health (http://www.clinicaltrials.gov, NCT01647191). Registered 23 July 2012.
Literature
1.
go back to reference Gower E, Estes C, Blach S, Razavishearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:45–57.CrossRef Gower E, Estes C, Blach S, Razavishearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:45–57.CrossRef
2.
go back to reference Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 2013;28(1):7–10.CrossRefPubMed Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 2013;28(1):7–10.CrossRefPubMed
3.
go back to reference Jian L, Zhou Y, Lin X, Jiang Y, Tian R, Zhang Y, Wu J, Zhang F, Zhang Y, Wang Y, Bi S. General epidemiological parameters of viral hepatitis a, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS One. 2009;4(12):e8467.CrossRef Jian L, Zhou Y, Lin X, Jiang Y, Tian R, Zhang Y, Wu J, Zhang F, Zhang Y, Wang Y, Bi S. General epidemiological parameters of viral hepatitis a, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS One. 2009;4(12):e8467.CrossRef
6.
go back to reference Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health. 2008;122(10):990–1003.CrossRefPubMed Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health. 2008;122(10):990–1003.CrossRefPubMed
7.
go back to reference Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553–62.CrossRefPubMed Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553–62.CrossRefPubMed
8.
go back to reference Ly KN. HCV surpassed HIV as cause of death among Americans. Infectious Disease News. 2012;25(3):15. Ly KN. HCV surpassed HIV as cause of death among Americans. Infectious Disease News. 2012;25(3):15.
9.
go back to reference Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 2014;21(l):34–59.CrossRefPubMed Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 2014;21(l):34–59.CrossRefPubMed
10.
go back to reference van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour J-F, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HLA. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.CrossRefPubMed van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour J-F, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HLA. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.CrossRefPubMed
11.
go back to reference Grebely J, Matthews GV, Lloyd AR, Dore GJ. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clin Infect Dis. 2013;57(7):1014–20.CrossRefPubMed Grebely J, Matthews GV, Lloyd AR, Dore GJ. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clin Infect Dis. 2013;57(7):1014–20.CrossRefPubMed
12.
go back to reference Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10:7.CrossRefPubMedPubMedCentral Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10:7.CrossRefPubMedPubMedCentral
13.
go back to reference Mravčík V, Strada L, Štolfa J, et al. Factors associated with the uptake, adherence and efficacy of hepatitis C treatment among people who inject drugs: a literature review. Patient Prefer Adherence. 2013;7:1067–75.CrossRefPubMedPubMedCentral Mravčík V, Strada L, Štolfa J, et al. Factors associated with the uptake, adherence and efficacy of hepatitis C treatment among people who inject drugs: a literature review. Patient Prefer Adherence. 2013;7:1067–75.CrossRefPubMedPubMedCentral
14.
go back to reference NIH Consens State Sci Statements. NIH consensus statement on management of hepatitis C: 2002. NIH consensus and state-of-the-science statements. 2002;19(3):1–46. NIH Consens State Sci Statements. NIH consensus statement on management of hepatitis C: 2002. NIH consensus and state-of-the-science statements. 2002;19(3):1–46.
15.
go back to reference Chinese Society of Hepatology. Hepatitis C prevention guideline in China. Chin J Hepatol. 2004;l2(4):194–8. Chinese Society of Hepatology. Hepatitis C prevention guideline in China. Chin J Hepatol. 2004;l2(4):194–8.
16.
go back to reference National Center for AIDS/STD Control and Prevention, China CDC. Update on the ADIS/STD epidemic in China and main response in control and prevention in december,2016. Chinese Journal of AIDS & STD. 2016;4(22):549. National Center for AIDS/STD Control and Prevention, China CDC. Update on the ADIS/STD epidemic in China and main response in control and prevention in december,2016. Chinese Journal of AIDS & STD. 2016;4(22):549.
17.
go back to reference Wu ZY, Luo W, Sullivan S, Rou K, Lin P, Liu W, Ming Z. Evaluation of a needle social marketing strategy to control HIV among injecting drug users in China. AIDS. 2007;21(8):115–S122.CrossRef Wu ZY, Luo W, Sullivan S, Rou K, Lin P, Liu W, Ming Z. Evaluation of a needle social marketing strategy to control HIV among injecting drug users in China. AIDS. 2007;21(8):115–S122.CrossRef
18.
go back to reference Qian HZ, Schumacher JE, Chen HT, Ruan YH. Injection drug use and HIV/AIDS in China: review of current situation, prevention and policy implication. Harm Reduct J. 2006;3(4):28–42. Qian HZ, Schumacher JE, Chen HT, Ruan YH. Injection drug use and HIV/AIDS in China: review of current situation, prevention and policy implication. Harm Reduct J. 2006;3(4):28–42.
19.
go back to reference Du J, Wang Z, Zhang HH, Dong AZ, Fan CL, Yuan Y, Jiang HF, Zhao M. HCV knowledge and HCV infection among drug users treated in a methadone maintenance treatment clinic. Chinese Journal of Drug Dependence. 2009;18(6):495–9. Du J, Wang Z, Zhang HH, Dong AZ, Fan CL, Yuan Y, Jiang HF, Zhao M. HCV knowledge and HCV infection among drug users treated in a methadone maintenance treatment clinic. Chinese Journal of Drug Dependence. 2009;18(6):495–9.
20.
go back to reference Michael PC, Morrison D, Blair TJ. The HIV-knowledge questionnaire: development and evaluation of a reliable, valid and practical self-administered questionnaire. AIDS Behav. 1997;1:61–74.CrossRef Michael PC, Morrison D, Blair TJ. The HIV-knowledge questionnaire: development and evaluation of a reliable, valid and practical self-administered questionnaire. AIDS Behav. 1997;1:61–74.CrossRef
21.
go back to reference Zule WA, Costenbader EC, Coomes CM, Wechsberg WM. Effects of a hepatitis C virus educational intervention or a motivational intervention on alcohol use, injection drug use, and sexual risk behaviors among injection drug users. Am J Public Health. 2009; 99,1(1):180–186.CrossRefPubMedPubMedCentral Zule WA, Costenbader EC, Coomes CM, Wechsberg WM. Effects of a hepatitis C virus educational intervention or a motivational intervention on alcohol use, injection drug use, and sexual risk behaviors among injection drug users. Am J Public Health. 2009; 99,1(1):180–186.CrossRefPubMedPubMedCentral
22.
go back to reference Kapadia F, Latka MH, Hagan H, Golub ET, Campbell JV, Coady MH, Garfein RS, Thomas DL, Bonner S, Thiel T, Strathdee SA. Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis c virus positive injection drug users: the study to reduce intravenous exposures (strive). J Urban Health. 2007;84(1):99–115.CrossRefPubMedPubMedCentral Kapadia F, Latka MH, Hagan H, Golub ET, Campbell JV, Coady MH, Garfein RS, Thomas DL, Bonner S, Thiel T, Strathdee SA. Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis c virus positive injection drug users: the study to reduce intravenous exposures (strive). J Urban Health. 2007;84(1):99–115.CrossRefPubMedPubMedCentral
23.
go back to reference Stein MD, Herman DS, Anderson BJ. A trial to reduce hepatitis C seroincidence in drug users. J Infect Dis. 2009;28(4):389–98. Stein MD, Herman DS, Anderson BJ. A trial to reduce hepatitis C seroincidence in drug users. J Infect Dis. 2009;28(4):389–98.
24.
go back to reference Norden L, Saxon L, Kåberg M, Käll K, Franck J, Lidman C. Knowledge of status and assessment of personal health consequences with hepatitis C are not enough to change risk behaviour among injecting drug users in Stockholm County. Sweden Scandinavian Journal of Infectious Diseases. 2009;41(10):727–34.CrossRefPubMed Norden L, Saxon L, Kåberg M, Käll K, Franck J, Lidman C. Knowledge of status and assessment of personal health consequences with hepatitis C are not enough to change risk behaviour among injecting drug users in Stockholm County. Sweden Scandinavian Journal of Infectious Diseases. 2009;41(10):727–34.CrossRefPubMed
25.
go back to reference Wang C, Shi CX, Rou K, Zhao Y, Cao X, Luo W, Liu E, Wu Z. Baseline HCV Antibody prevalence and risk factors among drug users in China’s National Methadone Maintenance Treatment Program. PLoS One. 2016;11(2):e0147922.CrossRefPubMedPubMedCentral Wang C, Shi CX, Rou K, Zhao Y, Cao X, Luo W, Liu E, Wu Z. Baseline HCV Antibody prevalence and risk factors among drug users in China’s National Methadone Maintenance Treatment Program. PLoS One. 2016;11(2):e0147922.CrossRefPubMedPubMedCentral
26.
go back to reference Nelson P, Mathers B, Cowie B, Hagan H, Jarlais DD, Horyniak D, Degenhardt L. The epidemiology of viral hepatitis among people who inject drugs: results of global systematic reviews. Lancet. 2011;378(9791):571–83.CrossRefPubMedPubMedCentral Nelson P, Mathers B, Cowie B, Hagan H, Jarlais DD, Horyniak D, Degenhardt L. The epidemiology of viral hepatitis among people who inject drugs: results of global systematic reviews. Lancet. 2011;378(9791):571–83.CrossRefPubMedPubMedCentral
27.
go back to reference Fisher JD, Fisher WA, Bryan AD, Misovich SJ. Information-motivation-behavioral skills model-based HIV risk behavior change intervention for inner-city high school youth. Health Psychol. 2002;21(2):177–86.CrossRefPubMed Fisher JD, Fisher WA, Bryan AD, Misovich SJ. Information-motivation-behavioral skills model-based HIV risk behavior change intervention for inner-city high school youth. Health Psychol. 2002;21(2):177–86.CrossRefPubMed
28.
29.
go back to reference Xun Z, Liang Y, Chow EPF, Wang Y, Wilson DP, Zhang L. HIV and HCV prevalence among entrants to methadone maintenance treatment clinics in China: a systematic review and meta-analysis. BMC Infect Dis. 2012;12(1):130.CrossRef Xun Z, Liang Y, Chow EPF, Wang Y, Wilson DP, Zhang L. HIV and HCV prevalence among entrants to methadone maintenance treatment clinics in China: a systematic review and meta-analysis. BMC Infect Dis. 2012;12(1):130.CrossRef
30.
go back to reference Hagan H, Pouget ER, Jarlais DCD. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204(1):74–83.CrossRefPubMedPubMedCentral Hagan H, Pouget ER, Jarlais DCD. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204(1):74–83.CrossRefPubMedPubMedCentral
31.
go back to reference Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57(2):39–45.CrossRef Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57(2):39–45.CrossRef
32.
go back to reference Hammett T, Wu Z, Duc TT, Stephens D, Sullivan S, Liu W, Chen Y, Ngu D, Des Jarlais DC. Social Evils’ and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam. Addiction. 2008;103(1):137–45.CrossRefPubMed Hammett T, Wu Z, Duc TT, Stephens D, Sullivan S, Liu W, Chen Y, Ngu D, Des Jarlais DC. Social Evils’ and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam. Addiction. 2008;103(1):137–45.CrossRefPubMed
33.
go back to reference Alavian SM, Mirahmadizadeh A, Javanbakht M, Keshtkaran A, Heidari A, Mashayekhi A, Salimi S, Hadian M. Effectiveness of methadone maintenance treatment in prevention of hepatitis C virus transmission among injecting drug users. Hepat Mon. 2013;13(8):e12411.CrossRefPubMedPubMedCentral Alavian SM, Mirahmadizadeh A, Javanbakht M, Keshtkaran A, Heidari A, Mashayekhi A, Salimi S, Hadian M. Effectiveness of methadone maintenance treatment in prevention of hepatitis C virus transmission among injecting drug users. Hepat Mon. 2013;13(8):e12411.CrossRefPubMedPubMedCentral
34.
go back to reference Mukherjee TI, Pillai V, Ali SH, Altice FL, Kamarulzaman A, Wickersham JA. Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia. The International journal on drug policy. 2017;47:144–52.CrossRefPubMedPubMedCentral Mukherjee TI, Pillai V, Ali SH, Altice FL, Kamarulzaman A, Wickersham JA. Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia. The International journal on drug policy. 2017;47:144–52.CrossRefPubMedPubMedCentral
Metadata
Title
DOES IT WORK? -a randomized controlled trial to test the efficacy of HCV and HIV-related education on drug users in MMT, China
Authors
Jing Ying Zhang
Zhi Bin Li
Lei Zhang
Jun Wang
Le Ping Huang
Gui Lai Zhan
Zhu Li
Jiang Du
Min Zhao
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2019
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-4421-5

Other articles of this Issue 1/2019

BMC Infectious Diseases 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.